摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-methyl-1,6-naphthyridin-4-amine | 1375471-84-3

中文名称
——
中文别名
——
英文名称
N-methyl-1,6-naphthyridin-4-amine
英文别名
——
N-methyl-1,6-naphthyridin-4-amine化学式
CAS
1375471-84-3
化学式
C9H9N3
mdl
MFCD21602709
分子量
159.19
InChiKey
LWYHQMKPGHIDIQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.111
  • 拓扑面积:
    37.8
  • 氢给体数:
    1
  • 氢受体数:
    3

文献信息

  • [EN] AKT3 MODULATORS<br/>[FR] MODULATEURS DE AKT3
    申请人:GEORGIAMUNE LLC
    公开号:WO2021226519A1
    公开(公告)日:2021-11-11
    Compounds of Formula la, lb, or Ic, are described, where the various substituents are defined herein. The compounds can modulate a property or effect of Akt3 in vitro or in vivo, and can also be used, individually or in combination with other agents, in the prevention or treatment of a variety of conditions. Methods for synthesizing the compounds are described. Pharmaceutical compositions and methods of using these compounds or compositions, individually or in combination with other agents or compositions, in the prevention or treatment of a variety of conditions are also described.
    公式Ia、Ib或Ic的化合物已被描述,其中各种取代基在此定义。这些化合物可以在体外或体内调节Akt3的性质或效果,并且也可以单独或与其他药剂结合在预防或治疗各种疾病方面使用。描述了合成这些化合物的方法。还描述了制药组合物以及使用这些化合物或组合物在预防或治疗各种疾病中单独或与其他药剂或组合物结合的方法。
  • HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS
    申请人:eFFECTOR Therapeutics, Inc.
    公开号:US20170145009A1
    公开(公告)日:2017-05-25
    The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula IA or Formula IB, as well as stereoisomers, tautomers or pharmaceutically acceptable salts thereof. For Formula IA and Formula IB compounds A 1 , A 2 , A 3 , A 4 , W 1 , W 2 , Y, X, R 1 , R 2 , R 3 , R 4a , R 4b , R 5a , R 5b , R 6 , R 7 , R 8 , R 9 , R 9a , R 9b , R 10 and subscript n are as defined in the specification. The inventive Formula IA and Formula IB compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
查看更多